Axsome begins Phase 3 trial of AXS-05 for smoking cessation

August 31, 2026 7:00 AM

Axsome Therapeutics (NASDAQ: AXSM) announced that the first patient has been dosed in the SUMMIT Phase 3 trial evaluating AXS-05 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found